Galderma received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA (Relfydess), its proposed competitor to Botox and Dysport. The CRL signals the agency will not approve the application in its current form, requiring additional data or manufacturing clarification before resubmission.
Regulatory
Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know
The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.
The CRL marks the second FDA setback for Galderma's neuromodulator entry, extending the timeline for a third botulinum toxin option in the U.S.
This is Galderma's second regulatory setback for the product. The delay extends the timeline for a third botulinum toxin option in the U.S. market—a space currently dominated by AbbVie's Botox and Revance's Dysport. For practices, the competitive pressure that might have driven pricing or rebate concessions from incumbents is now pushed further out. Galderma's stock fell sharply on the news, reflecting investor disappointment in the company's ability to diversify its injectables portfolio beyond Restylane fillers.
Source: original report ↗
Frequently asked questions
What is a Complete Response Letter from the FDA?
A Complete Response Letter (CRL) means the FDA will not approve a drug application in its current form and requires the manufacturer to submit additional data, clinical evidence, or manufacturing information before resubmission. It's a formal rejection that delays market entry but allows the company to address specific deficiencies and reapply.
When will Relfydess be available in the US?
Relfydess does not have an approved timeline for U.S. market entry. Galderma received a Complete Response Letter, meaning the product must undergo additional FDA review and resubmission before approval is possible. The delay extends beyond the original expected timeline.
How many botulinum toxin brands are available in the US?
Currently, two botulinum toxin brands dominate the U.S. market: AbbVie's Botox and Revance's Dysport. Relfydess would have been the third option, but its FDA approval is now delayed due to the Complete Response Letter.
Will Relfydess approval affect Botox and Dysport pricing?
The FDA delay for Relfydess removes near-term competitive pressure that could have driven price concessions or rebates from Botox and Dysport manufacturers. Practices should not expect pricing changes from incumbents in the near future as a result of this setback.
Is this Galderma's first FDA rejection for Relfydess?
No, this is Galderma's second regulatory setback for RelabotulinumtoxinA. The company has previously encountered FDA obstacles, indicating ongoing challenges in meeting the agency's approval requirements for this product.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.